about the author

Amber Tong

amber@endpointsnews.com @AmberTongPW
Amber Tong on LinkedIn

author articles

Fre­quen­cy fol­lows Astel­las pact with $62M round to bankroll PhII of lead re­gen­er­a­tive drug

6 years ago
Financing

Ver­tex gets NDA go­ing for CF triple com­bo; Dis­arm woos rare dis­ease ex­pert Alvin Shih as CEO

6 years ago
News Briefing

Take­da re­ports sec­ond PhI­II win for sub­cu­ta­neous En­tyvio as reg­u­la­tors re­view ex­pand­ed use

6 years ago
R&D
Pharma

Cel­gene racks up third Ote­zla ap­proval, heat­ing up talks about who Bris­tol-My­ers will sell to

6 years ago
Deals
Pharma

Chas­ing Roche's ag­ing block­buster fran­chise, Am­gen/Al­ler­gan roll out Avastin, Her­ceptin knock­offs at dis­count

6 years ago
Pharma

Cu­ri­ous case of stock price moves re­veals Sum­it­o­mo Dainip­pon is eye­ing $202M buy­out of Aus­tralian stem cell play­er

6 years ago
Deals

Chardan's blank check com­pa­ny picks mi­cro­bio­me play­er Bio­mX for $70M re­verse merg­er

6 years ago
Startups

Biotech uni­corns first to go as Neil Wood­ford auc­tions as­sets off sus­pend­ed fund — re­port

6 years ago
People
Financing

FDA over­rides ad­comm opin­ions a fifth of the time, study finds — but why?

6 years ago
FDA+

Fol­low­ing foot­steps of chart-top­ping Chi­nese coun­ter­parts, Al­pham­ab On­col­o­gy files IPO at HKEX

6 years ago
Financing
China

Bay­er, Long­wood back star re­searcher's deep dive in­to the tu­mor mi­croen­vi­ron­ment for new I/O tar­gets

6 years ago
Financing
Startups

In­ovio ax­es staff, chops R&D pro­grams in chase for elu­sive com­mer­cial win — though there's still a lot on their ...

6 years ago
People

Keen to stay out front in cell ther­a­py, Gilead­'s Kite builds its own vi­ral vec­tor man­u­fac­tur­ing op­er­a­tions

6 years ago
Cell/Gene Tx

San Diego oph­thalmic biotech up­start rais­es $28M on al­ter­na­tive to corneal trans­plant

6 years ago
Financing
Startups

AM-Phar­ma gath­ers €116M for PhI­II pro­gram on kid­ney drug Pfiz­er passed on

6 years ago
Financing

Mi­cro­cap Capri­cor soars on in­ter­im PhII DMD da­ta show­ing func­tion­al ben­e­fit for old­er pa­tients

6 years ago
R&D
Cell/Gene Tx

Eton Phar­ma hand­ed CRL for re­for­mu­lat­ed con­junc­tivi­tis eye drop

6 years ago
R&D
FDA+

GSK to tap Jonathan Symonds as chair­man, lever­ag­ing Big Phar­ma ex­pe­ri­ence for con­sumer biz deal

6 years ago
People

Sofinno­va lends Abi­Vax a hand for PhII an­ti-in­flam­ma­to­ry tri­als, pick­ing up €12M worth of stock

6 years ago
Financing

Su­per­charg­ing CAR-T with can­cer vac­cine, MIT team spot­lights some new tech un­der­pin­ning Dar­rell Irvine's start­up

6 years ago
Discovery
Cell/Gene Tx

No clear an­swers: Yes, re­cent ac­tions against Chi­nese Amer­i­can sci­en­tists do pose a threat — but maybe those ...

6 years ago
People
China

White House changes course to kill re­bate re­form

6 years ago
Pharma

As­tex vet Neil Thomp­son looks to build dis­cov­ery from scratch at rare dis­ease AI up­start out of Cam­bridge, UK

6 years ago
People
AI

Sanofi be­gins count­down for FDA isat­ux­imab re­view; Cir­rho­sis-fo­cused biotech presents an­oth­er mi­ni IPO

6 years ago
News Briefing
First page Previous page 949596979899100 Next page Last page
A service from the Financial Times